Financhill
Sell
37

LPCN Quote, Financials, Valuation and Earnings

Last price:
$4.67
Seasonality move :
15.6%
Day range:
$4.81 - $4.93
52-week range:
$2.44 - $11.79
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
5.45x
P/B ratio:
1.37x
Volume:
7K
Avg. volume:
28.2K
1-year change:
66.6%
Market cap:
$26.2M
Revenue:
-$2.9M
EPS (TTM):
-$0.77

Analysts' Opinion

  • Consensus Rating
    Lipocine has received a consensus rating of --. The company's average rating is a -- based on 0 Buy ratings, 0 Hold ratings, and 0 Sell ratings.
  • Price Target Upside
    According to analysts' consensus price target of --, Lipocine has an estimated upside of 338.95% from its current price of $4.90.
  • Price Target Downside
    According to analysts, the lowest downside price target is -- representing 100% downside risk from its current price of $4.90.

Fair Value

  • According to the consensus of 0 analysts, Lipocine has 338.95% upside to fair value with a price target of -- per share.

LPCN vs. S&P 500

  • Over the past 5 trading days, Lipocine has underperformed the S&P 500 by -8.68% suggesting its relative strength compared to the major market average is weak at this time.

Share Buyback

  • Lipocine does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.

Revenue Growth

  • Lipocine has grown year-over-year revenues for 0 quarters straight. In the most recent quarter Lipocine reported revenues of $89.6K.

Earnings Growth

  • Lipocine has grown year-over-year earnings for 0 quarters straight. In the most recent quarter Lipocine reported earnings per share of -$0.44.
Enterprise value:
6.4M
EV / Invested capital:
--
Price / LTM sales:
5.45x
EV / EBIT:
--
EV / Revenue:
1.33x
PEG ratio (5yr expected):
--
EV / Free cash flow:
-1.27x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
--
Return On Assets:
-33.49%
Net Income Margin (TTM):
-176.8%
Return On Equity:
-36.41%
Return On Invested Capital:
-36.41%
Operating Margin:
-3676.18%
Trailing 12 Months Fiscal Quarters
Period Ending 2022-09-30 2023-09-30 2024-09-30 2023-09-30 2024-09-30
Income Statement
Revenue -- -- -- -$3.1M --
Gross Profit -- -- -- -- --
Operating Income $3.2M -$17.9M -$5.3M -$7M -$2.6M
EBITDA $4.2M -$17.5M -$3.7M -$7M -$2.6M
Diluted EPS $0.57 -$3.14 -$0.77 -$1.27 -$0.44
Period Ending 2020-09-30 2021-09-30 2022-09-30 2023-09-30 2024-09-30
Balance Sheet
Current Assets $24.7M $40.4M $36.1M $24.6M $20.5M
Total Assets $24.8M $40.4M $39.4M $24.8M $20.7M
Current Liabilities $5.8M $6.4M $1.5M $2.2M $1.6M
Total Liabilities $10.2M $7.6M $1.8M $2.3M $1.6M
Total Equity $14.5M $32.8M $37.6M $22.5M $19.1M
Total Debt $6.4M $3.1M -- -- --
Trailing 12 Months Fiscal Quarters
Period Ending 2022-09-30 2023-09-30 2024-09-30 2023-09-30 2024-09-30
Cash Flow Statement
Cash Flow Operations -$1.1M -$11.7M -$4.9M -$2.6M -$2.8M
Cash From Investing $2M $13M $4.4M $1.2M $1M
Cash From Financing -$3M $404K $204K $421.1K --
Free Cash Flow -$1.2M -$11.8M -$5M -$2.6M -$2.9M
LPCN
Sector
Market Cap
$26.2M
$46.1M
Price % of 52-Week High
41.55%
46.02%
Dividend Yield
0%
0%
Shareholder Yield
--
-0.6%
1-Year Price Total Return
66.6%
-30.52%
Beta (5-Year)
1.240
0.772
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Technicals

8-day SMA
Sell
Level $4.90
200-day SMA
Sell
Level $5.40
Bollinger Bands (100)
Buy
Level 4.06 - 5.38
Chaikin Money Flow
Buy
Level 3.2M
20-day SMA
Buy
Level $4.88
Relative Strength Index (RSI14)
Sell
Level 48.42
ADX Line
Sell
Level 25.13
Williams %R
Neutral
Level -63.6182
50-day SMA
Sell
Level $5.15
MACD (12, 26)
Sell
Level -0.04
25-day Aroon Oscillator
Buy
Level 44
On Balance Volume
Neutral
Level 60.1M

Financial Scores

Sell
Altman Z-Score (Annual)
Level (-10.1928)
Sell
CA Score (Annual)
Level (-0.9866)
--
Beneish M-Score (Annual)
Level (--)
Buy
Momentum Score
Level (10)
Sell
Ohlson Score
Level (11.0869)
--
Piotroski F Score (Annual)
Level (--)
--
Quality Ratio Score
Level (--)
Sell
Fundamental Score
Level (1)

Revenue Forecast

Earnings per Share Forecast

Company Profile

Lipocine Inc is a clinical-stage biopharmaceutical company. It is focused on oral drug delivery technology for the development of pharmaceutical products focusing on metabolic and endocrine disorders. The company's product TLANDO is an oral testosterone replacement therapy ("TRT"). It also has other products in the pipeline such as LPCN 1144, LPCN 1148, and LPCN 1107. The Company has single reportable segment being, research and development for the delivery of drugs using its proprietary delivery technology.

Stock Forecast FAQ

In the current month, LPCN has received 0 Buy ratings 0 Hold ratings, and 0 Sell ratings. The LPCN average analyst price target in the past 3 months is --.

  • Where Will Lipocine Stock Be In 1 Year?

    According to analysts, the consensus estimate is that Lipocine share price will rise to -- per share over the next 12 months.

  • What Do Analysts Say About Lipocine?

    Analysts are divided on their view about Lipocine share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Lipocine is a Sell and believe this share price will drop from its current level to --.

  • What Is Lipocine's Price Target?

    The price target for Lipocine over the next 1-year time period is forecast to be -- according to 0 Wall Street analysts, 0 of them rate the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.

  • Is LPCN A Buy, Sell Or Hold?

    According to Wall Street analysts, the consensus rating for Lipocine is a --. 0 of 0 analysts rate the stock a -- at this time.

  • How Can I Buy Shares Of LPCN?

    You can purchase shares of Lipocine via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, TastyTrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Lipocine shares.

  • What Is The Lipocine Share Price Today?

    Lipocine was last trading at $4.67 per share. This represents the most recent stock quote for Lipocine. Yesterday, Lipocine closed at $4.90 per share.

  • How To Buy Lipocine Stock Online?

    In order to purchase Lipocine stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Popular

How High Will Airbnb Stock Go?
How High Will Airbnb Stock Go?

Airbnb, Inc. (NASDAQ:ABNB) share price has seen substantial turbulence over…

Why Is SoundHound AI Stock Up So Much?
Why Is SoundHound AI Stock Up So Much?

Like many companies improving AI technologies and exploring ways to…

Is The Santa Claus Rally The Gift That Keeps Giving?
Is The Santa Claus Rally The Gift That Keeps Giving?

Remember the horror of 2008 when the Great Recession hit…

Stock Ideas

Buy
65
Is AAPL Stock a Buy?

Market Cap: $3.9T
P/E Ratio: 42x

Buy
57
Is NVDA Stock a Buy?

Market Cap: $3.4T
P/E Ratio: 118x

Buy
58
Is MSFT Stock a Buy?

Market Cap: $3.3T
P/E Ratio: 37x

Alerts

Buy
60
QMCO alert for Dec 26

Quantum [QMCO] is up 49.62% over the past day.

Buy
53
ARQQ alert for Dec 26

Arqit Quantum [ARQQ] is up 49.85% over the past day.

Buy
65
TSLL alert for Dec 26

Direxion Daily TSLA Bull 2X Shares [TSLL] is down 3.73% over the past day.

THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS

Show me the best stock